Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Vincerx Pharma, Inc.

Get SEC filing alerts via email and in your feed for Vincerx Pharma, Inc.

VINC

Vincerx Pharma, Inc.

About Vincerx Pharma, Inc.

Vincerx Pharma is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies using its VersAptx platform. It creates antibody and small molecule conjugates aimed at hematologic and solid tumors, emphasizing safety and efficacy. The company advances innovative bioconjugates, including ADCs and SMDCs, targeting specific tumor antigens, with a pipeline of product candidates in early and clinical development stages.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Vincerx Pharma, Inc.

1
1
Vincerx Pharma, Inc. Vincerx Pharma Reports $5 Million Net Loss, Plans Dissolution Amid Financial Challenges

Via official filing (AI summary) | about 1 year ago | 0 comments

2
1
Vincerx Pharma, Inc. Vincerx Pharma Reports $30.1 Million Net Loss for Fiscal Year 2024, Pursues Business Combination with QumulusAI

Via official filing (AI summary) | about 1 year ago | 0 comments

3
1
Vincerx Pharma, Inc. Vincerx Pharma Reports Significant Decrease in Cash and Cash Equivalents, Operating Expenses, and Net Loss

Via official filing (AI summary) | over 1 year ago | 0 comments